UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Feasibility of [F-18]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study

Islam, Shahriar; Inglese, Marianna; Grech-Sollars, Matthew; Aravind, Preetha; Dubash, Suraiya; Barwick, Tara D; O'Neill, Kevin; ... Aboagye, Eric O; + view all (2023) Feasibility of [F-18]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study. European Journal of Nuclear Medicine and Molecular Imaging , 50 (13) pp. 3982-3995. 10.1007/s00259-023-06330-0. Green open access

[thumbnail of Feasibility of [sup18supF]fluoropivalate hybrid PETMRI for imaging lower and higher grade glioma a prospective first-in-pati.pdf]
Preview
PDF
Feasibility of [sup18supF]fluoropivalate hybrid PETMRI for imaging lower and higher grade glioma a prospective first-in-pati.pdf - Published Version

Download (1MB) | Preview

Abstract

Purpose: MRI and PET are used in neuro-oncology for the detection and characterisation of lesions for malignancy to target surgical biopsy and to plan surgical resections or stereotactic radiosurgery. The critical role of short-chain fatty acids (SCFAs) in brain tumour biology has come to the forefront. The non-metabolised SCFA radiotracer, [18F]fluoropivalate (FPIA), shows low background signal in most tissues except eliminating organs and has appropriate human dosimetry. Tumour uptake of the radiotracer is, however, unknown. We investigated the uptake characteristics of FPIA in this pilot PET/MRI study. Methods: Ten adult glioma subjects were identified based on radiological features using standard-of-care MRI prior to any surgical intervention, with subsequent histopathological confirmation of glioma subtype and grade (lower-grade – LGG – and higher-grade – HGG – patients). FPIA was injected as an intravenous bolus injection (range 342–368 MBq), and dynamic PET and MRI data were acquired simultaneously over 66 min. Results: All patients tolerated the PET/MRI protocol. Three patients were reclassified following resection and histology. Tumour maximum standardised uptake value (SUVmax,60) increased in the order LGG (WHO grade 2) < HGG (WHO grade 3) < HGG (WHO grade 4). The net irreversible solute transfer, Ki, and influx rate constant, K1, were significantly higher in HGG (p < 0.05). Of the MRI variables studied, DCE-MRI-derived extravascular-and-extracellular volume fraction (ve) was high in tumours of WHO grade 4 compared with other grades (p < 0.05). SLC25A20 protein expression was higher in HGG compared with LGG. Conclusion: Tumoural FPIA PET uptake is higher in HGG compared to LGG. This study supports further investigation of FPIA PET/MRI for brain tumour imaging in a larger patient population. Clinical trial registration: Clinicaltrials.gov, NCT04097535.

Type: Article
Title: Feasibility of [F-18]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study
Location: Germany
Open access status: An open access version is available from UCL Discovery
DOI: 10.1007/s00259-023-06330-0
Publisher version: https://doi.org/10.1007/s00259-023-06330-0
Language: English
Additional information: © 2023 Springer Nature. This article is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
Keywords: [18F]fluoropivalate, FPIA, PET/MRI, Glioma Short-chain fatty acid
UCL classification: UCL
UCL > Provost and Vice Provost Offices > UCL BEAMS
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Computer Science
URI: https://discovery.ucl.ac.uk/id/eprint/10183729
Downloads since deposit
5Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item